Literature DB >> 23921688

Bleeding associated with acquired factor V inhibitor in a patient on warfarin treated successfully with prednisolone.

Alhossain Khalafallah1, Julian Grabek, Robert Hayes, Muhajir Mohamed.   

Abstract

An 85-year-old man on warfarin for atrial fibrillation presented with skin bleeding. International normalised ratio (INR) and activated partial thromboplastin time (APTT) were elevated and did not correct even after warfarin reversal with vitamin K, prothrombin complex concentrate (PCC) and fresh frozen plasma. Mixing coagulation studies with normal plasma suggested the presence of an inhibitor rather than the multiple coagulation factor deficiencies expected with warfarin. Assays of the common-pathway coagulation factors revealed factor V concentration <2% with inhibitor level elevated to 11 Bethesda units. The bleeding resolved following a course of corticosteroids. Coagulation studies and factor V level returned to normal along with resolution of the inhibitor. We report the case of the diagnostic dilemma posed and successful therapy implemented despite the limited evidence-based data being available for the treatment of this rare condition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921688      PMCID: PMC3762120          DOI: 10.1136/bcr-2013-010018

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Acquired factor V inhibitor in systemic vasculitis.

Authors:  Chu-Oi Ciang; Moon-Ho Leung
Journal:  Int J Rheum Dis       Date:  2011-09-21       Impact factor: 2.454

Review 2.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

3.  Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation.

Authors:  Emmanuel J Favaloro; Jennifer Posen; Raj Ramakrishna; Soma Soltani; Simon McRae; Sarah Just; Margaret Aboud; Joyce Low; Rosalie Gemmell; Geoff Kershaw; Robyn Coleman; Mark Dean
Journal:  Blood Coagul Fibrinolysis       Date:  2004-10       Impact factor: 1.276

4.  Spectrum of bleeding in acquired factor V inhibitor: a summary of 33 cases.

Authors:  Viroj Wiwanitkit
Journal:  Clin Appl Thromb Hemost       Date:  2006-10       Impact factor: 2.389

5.  Deep-vein thrombosis and coumarin skin necrosis associated with a factor V inhibitor with lupus-like features.

Authors:  P W Kamphuisen; J Haan; P C Rosekrans; F J Van Der Meer
Journal:  Am J Hematol       Date:  1998-02       Impact factor: 10.047

6.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

Authors:  Peter W Collins; Sybil Hirsch; Trevor P Baglin; Gerard Dolan; John Hanley; Michael Makris; David M Keeling; Ri Liesner; Simon A Brown; Charles R M Hay
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

Review 7.  Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure.

Authors:  Michael B Streiff; Paul M Ness
Journal:  Transfusion       Date:  2002-01       Impact factor: 3.157

Review 8.  Acquired factor V inhibitor. A problem-based systematic review.

Authors:  Ai Leen Ang; Ponnudurai Kuperan; Chin Hin Ng; Heng Joo Ng
Journal:  Thromb Haemost       Date:  2009-05       Impact factor: 5.249

9.  Factor V inhibitor associated with Sjögren's syndrome.

Authors:  T Koyama; T Saito; T Kusano; S Hirosawa
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

  9 in total
  4 in total

1.  Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan.

Authors:  Masahiro Ieko; Kazumasa Ohmura; Sumiyoshi Naito; Mika Yoshida; Makoto Saito; Kazuki Kiyohara; Shinri Miyazima; Takahiro Maeta; Akihiro Ohtsu; Kenji Shimosegawa; Nobuhiko Takahashi; Akitada Ichinose
Journal:  Int J Hematol       Date:  2021-09-02       Impact factor: 2.490

2.  Acquired Factor V Inhibitor.

Authors:  Daisuke Hirai; Yugo Yamashita; Nobutoyo Masunaga; Toshiaki Katsura; Masaharu Akao; Yoshiaki Okuno; Hiroshi Koyama
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

3.  Acquired Factor V Inhibitors in a Patient with End-stage Renal Disease.

Authors:  Atsushi Kitazawa; Hideo Misawa; Katsuhiro Nagahori; Ryo Koda; Atsunori Yoshino; Shinya Kawamoto; Tetsuro Takeda
Journal:  Intern Med       Date:  2016-12-01       Impact factor: 1.271

4.  Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease.

Authors:  Eisuke Katsuren; Kentaro Kohagura; Takanori Kinjyo; Ryo Zamami; Takuto Nakamura; Nanako Oshiro; Yoshitsugu Sunagawa; Kumiko Omine; Yuki Kudo; Yuki Shinzato; Tsukasa Osaki; Masayoshi Souri; Akitada Ichinose; Masanobu Yamazato; Akio Ishida; Yusuke Ohya
Journal:  CEN Case Rep       Date:  2022-08-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.